S100B Antibody
- Known as:
- S100B Antibody
- Catalog number:
- csb-ma0206411a0m
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- CusAb
- Gene target:
- S100B Antibody
Related genes to: S100B Antibody
- Gene:
- S100B NIH gene
- Name:
- S100 calcium binding protein B
- Previous symbol:
- -
- Synonyms:
- S100beta
- Chromosome:
- 21q22.3
- Locus Type:
- gene with protein product
- Date approved:
- 1988-06-27
- Date modifiied:
- 2014-11-18
Related products to: S100B Antibody
Related articles to: S100B Antibody
- : Controlled hypotension during functional endoscopic sinus surgery (FESS) improves surgical field visibility but may pose a risk of subclinical cerebral hypoperfusion. Serum S100Β and neuron-specific enolase (NSE) are established biomarkers of glial and neuronal injury and may reflect perioperative neuroprotection associated with different anesthetic regimens. This study evaluated the effect of four anesthetic protocols on perioperative brain biomarker release during FESS. : In this single-center, randomized, controlled trial, 88 adult patients (ASA I-III) undergoing FESS under moderately controlled hypotension (mean arterial pressure < 55 mmHg) were allocated to one of four groups: propofol-remifentanil, propofol-remifentanil with ketamine-magnesium, sevoflurane-remifentanil, or sevoflurane-remifentanil with ketamine-magnesium. Serum S100Β and NSE concentrations were measured at three timepoints: early intraoperatively, during hypotension, and at the end of surgery. Biomarker data were analyzed using nested ANOVA and linear mixed-effects models adjusted for relevant covariates. Secondary outcomes included recovery characteristics, surgical field quality, bleeding scores, and perioperative hemodynamics. : Baseline demographic and perioperative characteristics were comparable across groups. The group receiving sevoflurane-remifentanil combined with ketamine-magnesium showed the lowest S100B levels ( = 0.01 compared to the propofol-remifentanil group; = 0.04 compared to the sevoflurane-remifentanil group). Additionally, NSE concentrations were markedly lower in both sevoflurane groups (sevoflurane-remifentanil and sevoflurane-remifentanil plus ketamine-magnesium) compared to the propofol-remifentanil group ( = 0.003 and = 0.007, respectively). No intergroup differences were observed at baseline and surgical field quality, bleeding, and hemodynamic parameters did not differ significantly among groups. Recovery and extubation times were shortest with propofol-remifentanil, whereas ketamine-magnesium prolonged emergence. : Anesthetic technique significantly influences perioperative brain biomarker release during FESS. Sevoflurane-based regimens, with or without ketamine-magnesium, demonstrate more favorable neurobiological profiles under controlled hypotension, although propofol-based anesthesia offers faster recovery. - Source: PubMed
Publication date: 2026/05/22
Rizopoulou SotiriaLygeros Spyridonde Lastic Anne-LiseGeorgakopoulou DimitraDaniilidis GerasimosVoulgary AthanasiaAretha Diamanto - Strict hemodynamic stability is critical during supratentorial craniotomy. This systematic review and meta-analysis aimed to evaluate the efficacy of magnesium sulfate (MgSO) as a multimodal adjuvant on intraoperative hemodynamics, opioid consumption, and biomarker outcomes in this setting. We systematically searched PubMed, Scopus, EBSCO, and the Cochrane Library for randomized controlled trials (RCTs) comparing perioperative MgSO administration to placebo or standard care in adult patients undergoing elective supratentorial craniotomy. Meta-analysis of nine included RCTs using a random-effects model demonstrated that MgSO significantly reduced intraoperative mean arterial pressure (mean difference [MD]: -4.65 mmHg; 95% confidence interval [CI]: -7.76 to -1.55; = 0.0033; I = 73.6%). Furthermore, MgSO administration significantly lowered postoperative serum S100B levels (standardized MD [SMD]: -0.81; 95% CI: -1.24 to -0.38; = 0.0002, I = 0.0%), indicating mitigated cellular neural damage, and decreased perioperative fentanyl consumption (standardized MD: -1.01; 95% CI: -1.45 to -0.57; < 0.0001; I = 0.0%). Intraoperative blood loss volume did not differ significantly between groups (MD: -85.03 mL; 95% CI: -331.42 to 161.37; = 0.4952; I = 92.5%). MgSO is a safe and effective multimodal adjuvant for supratentorial craniotomy, providing significant hemodynamic stability, opioid-sparing effects, and preliminary biochemical evidence suggestive of neuroprotection without compromising intraoperative hemostasis. - Source: PubMed
Publication date: 2026/06/15
Tarimah KhairunnisaiFu'adi IwanWiyarta ElvanAmalia LisdaBisri TatangBisri Dewi Yulianti - Despite the years that have passed since the pandemic, data regarding the effects of mild SARS-CoV-2 infection and vaccination during pregnancy remain limited. The current study investigated the expression of molecules that may be involved in the placental immune response using real-time PCR and Western blot analysis in a well-characterized cohort of 118 placentas collected between the 37th and 40th week of gestation. Secreted mediators were assessed in the supernatant of placental cell cultures, and histological examinations of the placental tissue were performed. Significant differences in the expression levels of , and were observed in control versus vaccinated and previously infected women, as determined by PCR. Acute SARS-CoV-2 infection decreased the expression of p38 MAPK and Bcl-2 compared to control patients. The secretion of G-CSF, IFN-α2, IL-2, and CXCL8 (IL-8) increased in women who were infected during pregnancy and/or vaccinated. However, histological analysis revealed only minor differences between the groups. In conclusion, SARS-CoV-2 infection or vaccination during pregnancy induced a measurable placental immune response that remained below the threshold of histologically detectable tissue injury. - Source: PubMed
Publication date: 2026/06/17
Hoymann NilsScholz LauraAlboradi SuzanGrabar ValeriiaUehre Gina MarieKhuankhunsathid Jakob TongTaube Eliane TabeaToth GeorgeMészáros JózsefGennari PaoloTchaikovski SvetlanaIgnatov AtanasBusse Mandy - Melanoma incidence rates have also been steadily increasing, emphasizing the need for improved prognostic and diagnostic tools with the goal of enhancing patients' outcomes. Biomarkers in melanoma have emerged as an important component of melanoma management, offering insight into disease progression, tumor biology, and the potential for judging treatment responses. Traditionally, blood and immunohistochemical markers such as lactate dehydrogenase (LDH), S100 calcium-binding protein (S100B), human melanoma black-45 (HMB-45), and SRY-box transcription factor 10 (SOX10) have been widely used in melanoma diagnosis, staging, and monitoring. However, their clinical use has been limited because of their low specificity, especially in patients with early-stage disease. This has led to the development of molecular and genetic biomarkers, including BRAF, NRAS, and KIT mutations, which improved patients' risk stratification and enabled targeted therapies, and gene expression signature assays such as DecisionDx (Castle Biosciences) and SkylineDx (Merlin) that are already used in clinics to help with surgical decisions and to assess patients' prognosis. Other circulating biomarkers, including microRNAs, circulating tumor DNA and circulating tumor cells, have been developed to provide minimally invasive approaches to monitor tumor evolution and detect recurrence. However, none of these new approaches are used in clinics due to their low specificity and/or sensitivity. Additionally, nomograms or predictive models have been created using biomarkers and clinicopathologic data to assess patients' outcomes and survival. While significant progress has been made, the integration of melanoma biomarkers into routine clinical practice remains limited. This review summarizes current advancements in melanoma biomarkers, including traditional serum and immunohistochemical markers, as well as developments in molecular, genetic, circulating, and predictive biomarker approaches. - Source: PubMed
Publication date: 2026/06/18
Crosby BrettGuerra MartinCrosby AlyssaLinza BenjaminLourdault KristelEssner Richard - Cord blood biomarkers could aid in the early diagnosis of neonatal encephalopathy (NE) and detect neonates likely to benefit from interventions. - Source: PubMed
Publication date: 2026/06/25
Rallis DimitriosSmolkova MagdalenaWalsh Brian HenryMurray DeirdreChristou HelenEl-Dib Mohamed